Trials / Unknown
UnknownNCT05914077
Aspiration of Duodenopancreatic Juice After Secretin Stimulation vs Endoscopic Aspiration for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia.
Aspiration of Duodenopancreatic Juice After Secretin Stimulation (ADPJ-secr-) vs Endoscopic Aspiration (EUS-FNA) for Molecular Analysis of Intraductal Papillary Mucinous Intraductal Neoplasia (IPMN).
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to evaluate aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr)versus endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis of intraductal papillary mucinous intraductal neoplasia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Secretin | Secretin will be administered intravenous during 1 minute at a dose of 0,2 μg/Kg previous to the endoscopic procedure. |
| PROCEDURE | Endoscopic aspiration | Endoscopic aspiration of duodenopancreatic juice after secretin stimulation |
| PROCEDURE | Endoscopic ultrasound-guided fine needle aspiration | Endoscopic ultrasound-guided fine needle aspiration of intraductal papillary mucinous intraductal neoplasia (IPMN). |
Timeline
- Start date
- 2023-09-13
- Primary completion
- 2025-01-01
- Completion
- 2025-01-01
- First posted
- 2023-06-22
- Last updated
- 2023-09-18
Locations
1 site across 1 country: Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05914077. Inclusion in this directory is not an endorsement.